Lyra Therapeutics (LYRA) Total Current Liabilities (2021 - 2025)
Historic Total Current Liabilities for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to $9.5 million.
- Lyra Therapeutics' Total Current Liabilities fell 3660.56% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year decrease of 3660.56%. This contributed to the annual value of $12.6 million for FY2024, which is 3554.63% down from last year.
- As of Q3 2025, Lyra Therapeutics' Total Current Liabilities stood at $9.5 million, which was down 3660.56% from $11.2 million recorded in Q2 2025.
- Over the past 5 years, Lyra Therapeutics' Total Current Liabilities peaked at $22.0 million during Q1 2022, and registered a low of $4.2 million during Q1 2021.
- For the 5-year period, Lyra Therapeutics' Total Current Liabilities averaged around $14.3 million, with its median value being $14.2 million (2023).
- In the last 5 years, Lyra Therapeutics' Total Current Liabilities skyrocketed by 42673.86% in 2022 and then crashed by 4208.86% in 2025.
- Lyra Therapeutics' Total Current Liabilities (Quarter) stood at $18.2 million in 2021, then decreased by 20.69% to $14.5 million in 2022, then soared by 35.43% to $19.6 million in 2023, then tumbled by 35.55% to $12.6 million in 2024, then fell by 24.95% to $9.5 million in 2025.
- Its Total Current Liabilities stands at $9.5 million for Q3 2025, versus $11.2 million for Q2 2025 and $11.5 million for Q1 2025.